Determining the role of SGLT2 inhibitors (dapagliflozin) on progression of proteinuria among non-diabetic adult patients with chronic kidney disease: a randomized controlled trial
DOI:
https://doi.org/10.18203/2349-3933.ijam20253347Keywords:
Albumin creatinine ratio, Chronic kidney disease, Dapagliflozin, Glomerular filtration rate, Non-diabetic, Randomized control trialAbstract
Background: In patients with type 2 diabetes, SGLT2 inhibition lowers albuminuria and the risk of renal disease progression. Improvement in glycemic control is unlikely to be the only factor mediating these advantages. The goal of this study was to determine any possible benefit of the SGLT2 inhibitor among subjects with non-diabetic kidney disease. To determine the effect of SGLT2 inhibitor (Dapagliflozin) on proteinuria among subjects with non-diabetic kidney disease.
Methods: A randomized control trial was conducted at K.P.S PG institute of medicine in association with Department of Nephrology, GSVSPGI, GSVM medical college, Kanpur. Eligible subjects were adult patients with non-diabetic CKD with eGFR between 25-90 ml/min/1.73m2 and having proteinuria with urinary albumin creatinine ratio (ACR)>30 mg/g for more than 3 months. Subjects were randomized to receive either dapagliflozin (10 mg) or placebo.
Results: A total of 228 subjects were screened between June 2022 to May 2023. Sixty-seven subjects met the inclusion criteria and only 46 subjects consented to participate in the study. The subjects were randomized in 1:1 ratio to receive either intervention or placebo for duration of 6 months. At the end of 6 months study period the intervention group demonstrated a median (IQR) reduction of-9.99(-63.17 -(-4.78)) mg/g (p value<0.01) in ACR along with a median (IQR) increase in eGFR of 19.23 (3.85-23.81) ml/min/1.73m2 from baseline. The placebo group continued to show a constant decline in eGFR with a median reduction of -32.43 (-59.8- (-23.04)) ml/min/1.73m2 from baseline with no significant change in ACR.
Conclusions: Use of SGLT2i among subjects with non-diabetic kidney disease resulted in reduction of proteinuria and an improvement in the real function. Therefore, SGLT2i may also be used among patients with non-diabetic kidney disease to check its progression.
Metrics
References
Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):117–314. DOI: https://doi.org/10.1016/j.kint.2023.10.018
Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies. 2019:3-15. DOI: https://doi.org/10.1007/978-981-13-8871-2_1
Basu M, Pulai S, Neogi S, Banerjee M, Bhattacharyya NP, Sengupta S, et al. Prevalence of non-diabetic kidney disease and inability of clinical predictors to differentiate it from diabetic kidney disease: results from a prospectively performed renal biopsy study. BMJ Open Diabetes Res Care. 2022;10(6):3058. DOI: https://doi.org/10.1136/bmjdrc-2022-003058
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28. DOI: https://doi.org/10.1038/ki.2010.483
Sarzani R, Giulietti F, Di Pentima C, Spannella F. Sodium-glucose co-transporter-2 inhibitors: peculiar “hybrid” diuretics that protect from target organ damage and cardiovascular events. Nutrition, Metabol Cardiovas Dis. 2020;30(10):1622-32. DOI: https://doi.org/10.1016/j.numecd.2020.05.030
Koh ES, Kim GH, Chung S. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis. Endocrinol Metab. 2023;38(4):359–72. DOI: https://doi.org/10.3803/EnM.2023.1764
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England J Med. 2019;380(24):2295-306.
Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JF, McMurray JJ, Lindberg M, Rossing P, Sjöström CD. Dapagliflozin in patients with chronic kidney disease. New England J Med. 2020;383(15):1436-46.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582–93.
Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, et al. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. J Am Soc Nephrol JASN. 2021;32(2):436–47. DOI: https://doi.org/10.1681/ASN.2020030349
Correction to Lancet Diabetes Endocrinol 2021; 9: 743–54. Lancet Diabetes Endocrinol. 2022;10(1):10. DOI: https://doi.org/10.1016/S2213-8587(22)00223-6
Cherney DZ, Dekkers CC, Barbour SJ, Cattran D, Gafor AH, Greasley PJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diab Endocrinol. 2020;8(7):582-93. DOI: https://doi.org/10.1016/S2213-8587(20)30162-5
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436–46. DOI: https://doi.org/10.1056/NEJMoa2024816
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–306. DOI: https://doi.org/10.1056/NEJMoa1811744
Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020;35(10):1700–11. DOI: https://doi.org/10.1093/ndt/gfaa234
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9. DOI: https://doi.org/10.1016/S0140-6736(18)32590-X
Downloads
Published
How to Cite
Issue
Section
